Perspective Therapeutics, Inc. (NYSE:CATX) Stake Raised by Barclays PLC

Barclays PLC grew its holdings in shares of Perspective Therapeutics, Inc. (NYSE:CATX) by 587.9% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 114,075 shares of the company’s stock after purchasing an additional 97,493 shares during the period. Barclays PLC’s holdings in Perspective Therapeutics were worth $1,523,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. nVerses Capital LLC acquired a new stake in Perspective Therapeutics during the third quarter valued at approximately $57,000. US Bancorp DE increased its holdings in shares of Perspective Therapeutics by 142.7% in the third quarter. US Bancorp DE now owns 6,576 shares of the company’s stock valued at $88,000 after buying an additional 3,866 shares in the last quarter. Intech Investment Management LLC acquired a new stake in shares of Perspective Therapeutics during the 3rd quarter valued at $137,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Perspective Therapeutics during the 3rd quarter valued at $152,000. Finally, Los Angeles Capital Management LLC bought a new stake in shares of Perspective Therapeutics during the 3rd quarter worth $153,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

Insider Transactions at Perspective Therapeutics

In other news, CEO Johan M. Spoor purchased 8,000 shares of Perspective Therapeutics stock in a transaction dated Wednesday, December 4th. The stock was acquired at an average cost of $3.77 per share, for a total transaction of $30,160.00. Following the acquisition, the chief executive officer now directly owns 36,257 shares in the company, valued at $136,688.89. This represents a 28.31 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Heidi Henson purchased 25,975 shares of the stock in a transaction that occurred on Wednesday, December 4th. The stock was purchased at an average cost of $3.85 per share, with a total value of $100,003.75. Following the purchase, the director now owns 25,975 shares in the company, valued at $100,003.75. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 67,570 shares of company stock valued at $256,789. 3.52% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on CATX. UBS Group initiated coverage on Perspective Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $20.00 target price on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Perspective Therapeutics in a report on Monday, September 9th. Bank of America cut shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $24.00 to $5.00 in a report on Monday, November 25th. Royal Bank of Canada cut their price target on shares of Perspective Therapeutics from $25.00 to $16.00 and set an “outperform” rating on the stock in a report on Monday, November 25th. Finally, Truist Financial assumed coverage on shares of Perspective Therapeutics in a research report on Wednesday, September 25th. They issued a “buy” rating and a $21.00 price target for the company. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $15.14.

Perspective Therapeutics Trading Down 3.0 %

Shares of CATX opened at $3.19 on Friday. The business’s 50-day moving average is $6.86 and its 200-day moving average is $10.77. Perspective Therapeutics, Inc. has a fifty-two week low of $2.70 and a fifty-two week high of $19.05.

Perspective Therapeutics (NYSE:CATX) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) earnings per share for the quarter, meeting the consensus estimate of ($0.21). Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. The firm had revenue of $0.37 million for the quarter. Sell-side analysts predict that Perspective Therapeutics, Inc. will post -0.88 EPS for the current fiscal year.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.